53
BIBLIOGRAFIA
Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 349–350.
Angst F, Stassen HH, Clayton PJ, Angst J Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-81.
Akiskal HS Mood disorders: introduction and overview. In Comprehensive Textbook of Psychiatry, BJ Sadock and VA Sadock, eds, New York, Lippincott, Williams & Wilkins, 2000, pp. 1284-1298.
Arancibia S, Silhol M, Moulière F, Meffre J, Hollinger I, Maurice T, Tapia-Arancibia L Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Disease 2008; 31:316-326.
Arancio O and Chao MV Neurotrophins, synaptic plasticity and dementia. Curr Op Neurobiol 2007; 17:325-330.
Arvanitis DN, Ducatenzeiler A, Ou JN, Grodstein E, Andrews SD, Tendulkar SR, Ribeiro-da-Silva A, Szyf M, Cuello AC High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. J Neurochem 2007; 103(1):216–228.
Aydemir O, Deveci A, Taneli F The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2004; 29:261–265.
Aydemir O, Yalcin ES, Aksaray S, Kisa C, Yildirim SG, Uzbay T, Goka E BDNF changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(7):1256-60.
Bertram L, Lill CM, Tanzi RE The genetics of Alzheimer disease: back to the future. Neuron 2010; 68(2):270-81.
Black DW, Winokur G, Nasrallah A A multivariate analysis of the experience of 423 depressed inpatients treated with electroconvulsive therapy. Conv Ther 1993; 9:112-120.
Blake AD, Badway AC, Strowski MZ Delineating somatostatin's neuronal actions. Curr Drug Targets CNS Neurol Disord 2004; 3:153–160.
Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, Jellinger K, Tragl KH, Fischer P Plasma Amyloid Beta-42 Independently Predicts Both Late-Onset Depression and Alzheimer Disease. Am J Geriatr Psychiatry. 2010; in press.
Bocchio-Chiavetto L, Zanardini R, Bortolomasi M et al. Electroconvulsive therapy (ECT) increases serum brainderived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur. Neuropsychopharmacol. 2006; 16:620–624.
Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D et al. Familial Alzheimer’s diseaselinked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17:1005-1013.
54
Brambilla P, Glahn DC, Balestrieri M, Soares JC Magnetic resonance findings in bipolar disorder. Psychiatr Clin North Am 2005; 28:443–467.Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J et al. Inherent toxicity of aggregates
implies a common mechanism for protein mis-folding diseases. Nature 2002 ;416:507–11.
Bunney WE Jr & Davis JM Norepinephrine in depressive reactions. A review. Arch. Gen. Psychiatry 1965 13:483–494.
Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke U, Abramowski D, Jucker M, Staufenbiel M, Deller T Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci 2004; 24:2421–2430.
Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J Biol Chem 1992; 267:546-554.
Cannon M, Jones P, Gilvarry C, Rifkin L, McKenzie K, Foerster A, Murray RM Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry 1997; 154:1544–1550.
Casoli T, Di Stefano G, Giorgetti B, Grossi Y, Balietti M, Fattoretti P, Bertoni-Freddari C Release of amyloid-beta from high-density platelets: implications for Alzheimer’s disease pathology. Ann N Y Acad Sci 2007; 1096:170-178.
Cassano GB I disturbi dell’umore. In: Psicopatologia e cinica psichiatrica. UTET 2006: 262-320.
Cassano GB, Tundo A (a cura di) Lo spettro dell'umore. Psicopatologia e clinica. 2008; Elsevier Masson, Milano.
Castrén E Neurotrophic effects of antidepressant drugs. Curr. Op. in Pharmacology 2004; 4:58-64.
Castrén E Is mood chemistry? Nat. Rev Neuroscience 2005; 6:241-246.
Chen B, Dowlatshahi D, MacQueen GM, Wang J-F, Young LT Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50:260 –265. Chen M, Inestrosa NC, Ross GS, Fernandez HL Platelets are the primary source of amyloid-peptide in human blood. Biochem Biophys Res Commun. 1995; 213(1):96-103.
Chen QS, Wei WZ, Shimahara T, Xie CW Alzheimer amyloid-beta peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 2002; 77:354 –371.
Ciechanowski PS, Katon WJ, Russo JE Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 2000; 160:3278-85.
Clark L, Kempton MJ, Scarna A, Grasby PM, Goodwin GM Sustained attention-deficit confirmed in
euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression. Biol. Psychiatry 2005a; 57:183–187.
Clark L, Sarna A, Goodwin GM Impairment of executive function but not memory in first-degree relatives of
patients with bipolar I disorder and in euthymic patients with unipolar depression. Am J Psychiatry 2005b; 162:1980–1982.
55
Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, Cuomo V, Trabace L Soluble betaamyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 2010; 159(8):1704-15.
Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunov M Brain-derived neurotrophic factor is reduced
in Alzheimer's disease. Mol Brain Res 1997; 49:71–81.
Cotter D, Mackay D, Landau S, Kerwin R, Everall I Reduced glial cell density and neuronal size in the
anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58:545–553.
Coyle JT & Duman RS Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38:157–160.
Coyne JC, Fechner-Bates S, Schwenk TL Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen. Hosp. Psychiatry 1994; 16:267-76.
Cunha ABM, Frey BN, Andreazza AC, Goy JD, Rosa AR Goncalves CA, Santin A, Kapczinski F Serum BDNF is decreased in bipolar disorder during depressive and manic episodes. Neurosci Letters 2006; 398(3):215-219.
Daban C, Vieta E, Mackin P, Young AH Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28:469–480.
Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Roose SP, Sackeim HA ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disorders 2001; 3:95-104.
Deane R, Bell RD, Sagare A, Zlokovic BV Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8(1):16-30. Dell’Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, Massimetti G, Catena Dell’Osso M, Vizzaccaro C, Marazziti D, Piccinni A Associations between Brain-Derived Neurotrophic Factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 2010; 62(4):207-212.
de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000; 57(11):1071-1076.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 2002; 295(5563):2264-2267.
Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280(17):17294-300.
de Oliveira GS, Ceresér KM, Fernandes BS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009; 43: 1171–1174.
Devanand DP, Sackeim HA, Decina P, Prudic J The development of mania and organic euphoria during ECT. J Clin Psychiatry 1988; 49(2):69-71.
Devanand DP, Sano M, Tang MX et al. Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry 1996; 53:175–182.
56
Devanand DP, Polanco P, Cruz R, Shah S, Paykina N, Singh K, Majors L The efficacy of ECT in mixed affective states. J of ECT 2000; 16(1):32-37.Diagnostic and statistical manual for mental disorders, 4th ed.: DSM-IV-TR. Washington, D.C.: American Psychiatric Association, 2000.
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16:285–298.
Duman RS, Heninger GR & Nestler EJ A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997; 54:597-606.
Duman RS Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44:324-335. Duman RS Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5:11–25.
Dwivedi Y, Rao JS, Hooriyah SR, Kotowski J, Conley RR, Roberts RC, Tamminga CA, Pandey GN Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in post-mortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60:273–282.
Eisch A, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, Verhaagen J, Nestler EJ Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol Psychiatry 2003; 54:995–1005.
Evans DL and Charney DS Moos disorders and medical illness: a major public health problem. Biol. Psychiatry 2003; 54:177-180.
Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, Kuo CJ, Palmer TD VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 2003; 18:2803–2812.
Fava M Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53(8):649-659. Ferrier IN, Chowdhury R, Thompson JM, Watson S, Young AH Neurocognitive function in unaffected first-degree relatives of patients with bipolar disorder: a preliminary report. Bipolar Disord 2004; 6:319–322. Finkbeiner S CREB couples neurotrophin signals to survival messages. Neuron 2000; 25:11-14.
Folstein MF, Folstein SE, McHugh PR “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12:189.
Fumagalli F, Racagni G, Riva MA The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 2006 ; 6:8–15.
Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat
brain. Psychopharmacology 2001; 158:100–106.
Geerlings MI, Schoevers RA, Beekman AT et al. Depression and risk of cognitive decline and Alzheimer’s disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry 2000; 176:568–75.
Geerlings MI, den Heijer T, Koudstaal PJ et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008;70: 1258–1264.
57
Gervasoni N, Aubrey JM, Bondolfi G, Osiek G, Schwald M, Bertschv G, Karege F Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51:234 –238.Gibbons RD, Hur K, Bhaumik DK, Mann JJ The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165-72.
Goldman LS, Nielsen NH, Champion HC Awareness, diagnosis, and treatment of depression. J. Gen. Intern. Med. 1999; 14:569-80.
Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM Effects of b-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chemical Neuroanatomy 2003; 26: 153–169.
Goodwin FK, Jamison KR Manic-Depressive Ilness: bipolar disorders and recurrent depression. 2nd edition 2007; Oxford University Press, New York.
Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E Cognitive impairment in bipolar disorder : neurodevelopment or neurodegeneration ? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008; 18:787-793.
Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997; 17(7): 2492-2498.
Gonul A, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255(6):381–386. Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354– 362.
Gruber NP, Dilsaver SC, Shoaib AM, Swann AC ECT in mixed affective states: a case series. J ECT 2000; 16(2):183-188.
Gualtieri CT and Johnson LG Age-related cognitive decline in patients with mood disorders. Progr Neuropsychopharmacol Biol Psychiatry 2008; 32:962-967.
Guo Z, Zhou D & Schultz PG Designing small-molecule switches for protein–protein interactions. Science 2000; 288:2042–2045.
Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66(1):23-29.
Guy W ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch; 1976.
Hamilton M A rating scale for depression. J Neurol Neuro Neurosurg Psychiatry 1960; 23:56-62.
Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Muller OA, Stalla GK Human corticotropin-releasing hormone in depression. Biol. Psychiatry 1986; 21:601–611.
58
Honer WG, Falkai P, Bayer TA, Xie J, Hu l, Li HY, Arango V, Mann JJ, Dwork AJ, Trimble WS Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex 2002; 12:349-356.Hu Y, Yu X, Yang F et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 2010; 26: 121–125.
Hua JY & Smith SJ Neural activity and the dynamics of central nervous system development. Nature Neuroscience 2004; 7:327-332.
Huang TL, Lee CT, Liu YL Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatric Res 2007; 45:521–525.
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 2000; 408:979–982.
Jiang W, Krishnan RR, O’Connor CM Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16:111-27.
Johnson J, Horwath E, Weissman MM The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48:1075-81.
Jorge RE, Robinson RG, Arndt S, Starkstein S Mortality and post-stroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160:1823-9.
Kagan BL, Azimov R, Azimova R Amyloid peptide channels. J Membr Biol 2004; 202:1–10.
Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R APP processing and synaptic function. Neuron 2003; 37(6):925-37.
Kaplan HI, Sadock BJ: Manuale di scienze del comportamento e psichiatria clinica. Ottava edizione, Centro Scientifico Internazionale, Torino, 2001.
Karege F, Schwaldt M, Cisse M Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328:261-264.
Karege F, Perret H, Bondolfi G, Schwald M, Bertschv G, Aubrey JM Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychol Res 2002; 109:143–148.
Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G Low Brain Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57:1068-72.
Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136:29–37.
Katz LC & Shatz CJ Synaptic activity and the costruction of cortical circuits. Science 1996; 274:1133-1138.
Keller S, Sarchiapone M, Zaeeilli F et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 2010; 67: 258–267.
59
Kessing LV and Andersen PK Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75:1662-1666.Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ Amyloid-beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11:556–561.
Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, Arai H Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriatrics 2009;9(4):180-5.
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92(19):8856-60. Krishnan V, Nestler EJ The molecular neurobiology of depression. Nature 2008; 455:894–902.
Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006; 27:686–695.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta 1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95:6448–53.
Lang UE, Hellweg R, Gallinat J Low BDNF serum concentrations in healthy volunteers are associated with Depression-Related Personality traits. Neuropsychopharmacology 2004; 29:795-798.
Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006; 113:1217– 1224.
Levine ES, Crozier RA, Black IB & Plummer RM BDNF modulates hippocampal synaptic transmission by increasing NMDA receptor activity. Proc Natl Acad Sci USA 1998; 95:10235-10239.
Li CT, Lin CP, Chou KH, Chen IY, Hsieh JC, Wu CL, Lin WC, Su TP Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage 2010; 50:347-356.
Li N, He X, Qi X, Zhang Y, He S The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: Role of brain-derived neurotrophic factor. J Psychopharmacol 2010; 24(12):1772-8.
Lin PY State-dependent decrease in levels of brain derived neurotrophic factor in bipolar disorder: A metaanalytic study. Neurosci Lett. 2009; 466: 139–143.
Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 1996; 27(8):1274-1282.
Lu Y, Christian K, Lu B BDNF: A key regulator for protein synthesis dependent LTP and long term memory. Neurobiol Learn Mem 2008; 89:312–323.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J Soluble
amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 1999; 155:853–862.
60
Macedo-Soares MB, Moreno RA, Rigonatti SP, Lafer B Efficacy of electroconvulsive therapy intreatment-resistant bipolar disorder: a case series. J ECT 2005; 21(1):31-34.
Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain derived neurotrophic factor levels in
unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142–144.
Manji HK, Moore GJ, Rajkowska G & Chen G Neuroplasticity and cellular resilience in mood disorders.
Millennium article. Mol. Psychiatry 2000; 5:578–593.
Manji HK, Drevets WC & Charney DS The cellular neurobiology of depression. Nature Med. 2001; 7:541– 547.
Marano CM, Phatak P, Vemylapalli UR et al. Increased plasma concentration of brain-derived neurotrophic
factor with electroconvulsive therapy: A pilot study in patients with major depression. J Clin Psychiatry 2007; 68:512–517.
Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E The neuroprotective agent memantine
induces brain-derived Neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247–258.
Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE Amyloid-beta peptides destabilize
calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12:376–89.
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330(6012):1774.
Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD Plasma amyloid beta-peptide 1–42 and incipient Alzheimer’s disease. Ann Neurol 1999; 46:412–416. McCall WV, Dunn AG, Kellner CH Recent advances in the science of ECT: can the findings be generalized? J ECT 2000; 16(4):323-326.
McIntosh AM, Harrison LK, Forrester K, Lawrie SM, Johnstone EC Neuropsychological impairments in
people with schizophrenia or bipolar disorder and their unaffected relatives. Br J Psychiatry 2005; 186:378– 385.
McLean C A, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL Soluble
pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 1999; 46:860–866.
Monteleone P, Serritella C, Martiadis V, Maj M Decreased levels of serum brain-derived neurotrophic
factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10:95–100.
Moorhead TW, McKirdy J, Sussmann JE, Hall J, Lawrie SM, Johnstone EC, McIntosh AM Progressive
graymatter loss in patients with bipolar disorder. Biol Psychiatry 2007; 62: 894–900.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW Abeta peptide vaccination prevents
memory loss in an animal model of Alzheimer’s disease. Nature 2000; 408:982–985.
Mukherjee S, Sackeim HA, Schnur DB Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151(2):169-176.
61
Nelson RL, Guo Z, Halagappa VM et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 2007; 205:166–176.Nestler EJ Antidepressant treatment in the 21 st century. Biol. Psichiatry 1998; 44:526-533.
Nibuya M, Morinobu S, Duman RS Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539 –7547.
Nobler MS, Sackheim HA Electroconvulsive therapy. In Henn FA, Sartorius N, Helmchen H, Lauter H (Eds.) Contemporary Psychiatry 3:425-433, 2001; Springer, Berlin.
Okamoto T, Yoshimura R, Ikenouchi-Sugita A et al. Efficacy of electroconvulsive therapy is associated with
changing blood levels of homovanillic acid and brain derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1185–1190. O'Leary D, Gill D, Gregory S, Shawcross C Which depressed patients respond to ECT? The Nottingham
results. J Affect Disord 1995; 4;33(4):245-250.
Okereke OI, Xia W, Selkoe DJ, Grodstein F Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009; 66(10):1247-53.
Ongur D, Drevets WC, Price JL Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95:13290–13295.
Ownby RL, Crocco E, Acevedo A et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63:530–538.
Palomino A, Vallejo-Illarramendi A, González-Pinto A et al. Decreased levels of plasma BDNF in
first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006; 86: 321–322.
Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ Transport of BDNF across the blood-brain barrier Neuropharmacology 1998; 37(2):1553-1561.
Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y Brain-derived neurotrophic factor and
tyrosine kinase B receptor signaling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 2008; 11: 1047–1061.
Parker G, Roy K, Hadzi-Pavlovic D, Pedic F Psychotic (delusional) depression: a meta-analysis of physical
treatments. J Affect Disord 1992; 24(1):17-24.
Paykel ES Epidemiology of refractory depression. In Nolen WA, Zohar J, Roose SP, Amsterdam JD Refractory depression: current strategies and future directions. 1994; 3-18. Wiley, New York.
Peng S, Wuu J ,Mufson EJ, Fahnestock M Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005; 93:1412–1421.
Petrides G, Fink M The "half-age" stimulation strategy for ECT dosing. Conv Ther 1996; 12(3):138-146. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23(13):5531-5.
62
Piccinni A, Marazziti D, Catena M et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008; 105: 279–283. Piccinni A, Del Debbio A, Medda P, Bianchi C, Roncaglia I, Veltri A, Zanello S, Massimetti E, Origlia N, Domenici L, Marazziti D, Dell'Osso L Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009; 19(5):349-55. Pomara N, Doraiswamy PM, Willoughby LM et al. Elevation in plasma Abeta42 in geriatric depression: apilot study. Neurochem Res 2006; 31: 341–349.
Poo MM Neurotrophins as synaptic modulators. Nat. Rev. Neuroscience 2001; 2:24-32.
Popoli M, Gennarelli M, Racagni G Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord 2002; 4: 166-182.
Potter WZ, Rudorfer MV Electroconvulsive therapy - a modern medical procedure. NEJM1993; 328(12):882-883.
Preda S, Govoni S, Lanni C, Racchi M, Mura E, Grilli M et al. Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2008; 33: 1062–1070.
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153(8):985-989.
Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004; 55(3):301-312.
Qiu WQ, Sun X, Selkoe DJ et al. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007; 22:536–342.
Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996; 709(1): 122-301.
Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45:1085–1098.
Rapp MA, Schnaider-Beeri M, Grossman HT et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006; 63:161–167. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, Moore PB A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006; 93:105–115.
Sagare AP, Winkler EA, Bell RD, Deane R, Zlokovic BV From the liver to the Blood–Brain Barrier: an interconnected system regulating brain amyloid-beta levels. J Neurosci Res 2011; 89(7):967-8.
Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005; 11:434–439.
Saitoh T, Horsburgh K, Masliah E Hyperactivation of signal transduction systems in Alzheimer’s disease. Ann NY Acad Sci 1993; 695:34–41.
63
Sapolsky RM, Uno H, Rebert CS, Finch CE Hippocampal damage associated with prolonged stress exposure in primates. J Neurosci 1990; 9: 2897-2902.Sapolsky RM Glucocorticoids, stress and exacerbation of excitotoxic neuron death. Seminars in Neurosciences 1994; 6: 323-31.
Sapolsky RM Why stress is bad for your brain. Science 1996; 273: 749-750.
Sapolsky RM Stress, glucocorticoids, and damage to the nervous system: The current state of confusion. Stress 1996; 1: 1–19.
Sapolsky RM Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci USA 2001; 98:12320 –12322.
Sarrias MJ, Artigas F, Martinez E, Gelpi E, Alvarez E, Udina C, Casas M Decreased plasma serotonin in melancholic patients: A study with clomipramine. Biol Psychiatry 1987;22:1429 –1438.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996, 2:864-870.
Schnur DB, Mukherjee S, Sackeim HA, Lee C, Roth SD Symptomatic predictors of ECT response in medicationnonresponsive manic patients. J Clin Psychiatry 1992; 53(2):63-66.
Schröder J, Pantel J, Ida N et al. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer’s disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry 1997; 2: 505–507.
Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 1995; 92:1989–93.
Selkoe DJ The ups and downs of Abeta. Nat Med 2006; 12(7):758-759.
Sen S, Duman R, Sanacora G Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008; 64: 527–532.
Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 2010; 81(10):1123-7.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27:2866 –2875.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ Soluble amyloid-beta protein dimers isolated directly from Alzheimer disease patients potently impair synaptic plasticity and memory. Nat Med 2008; 14:837–842.
Sheehan DV, Lecrubier Y et al. Mini International Neuropsychiatric Interview (M.I.N.I.). University of South Florida Institute for Research in Psychiatry, Tampa, Florida and INSERM - Hopital de la Salpétrière, Paris, France, 1994.
Sheline YI, Gado MH, Kraemer HC Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160:1516–8.
64
Shergill SS, Katona CLE Pharmacotherapy of affective disorders. In Henn FA, Sartorius N, Helmchen H, Lauter H (Eds.) Contemporary Psychiatry 3:317-336, 2001; Springer, Berlin.Shimizu E, Hashimoto K, Olamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54:70 –75.
Shirayama Y, Chen AC-H, Nakagawa S, Russell RS, Duman RS Brain derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J Neurosci 2002; 22:3251–3261. Shi Y, You J, Yuan Y, Zhang X Plasma BDNF and tPA are associated with late-onset geriatric depression. Psychiatry Clin Neurosci 2010; 64: 239–248.
Shoffner JM Oxidative phosphorylation defects and Alzheimer’s disease. Neurogenetics 1997; 1:13–9. Shoji M, Golde TE, Ghiso J et al. Production of the Alzheimer amyloid-beta protein by normal proteolytic processing. Science 1992; 258:126–129.
Siuciak JA, Lewis DR, Wiegand SJ, Lindsay R Antidepressant-like effect of brain derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56:131–137.
Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, Small IF Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1998; 45(8):727-732.
Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8:1051– 1058.
Sobin C, Prudic J, Devanand DP, Nobler MS, Sackeim HA Who responds to electroconvulsive therapy? A comparison of effective and ineffective forms of treatment. Br J Psychiatry 1996; 169(3):322-328.
Sonne SC, Brady KT Substance abuse and bipolar comorbidity. A Review. Psychiatr Clin North Am 1999; 22(3):609-627.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9:83-91.
Spivak B, Vared Y, Graff E, Blum I, Mester R, Weizman A Low platelet-poor plasma concentration in patients with combat-related posttraumatic stress disorder. Biol Psychiatry 1999; 45:840-5.
Strakowski SM, DelBello MP, Fleck DE, Arndt S The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 15;48(6):477-485.
Strakowski SM, Delbello MP, Adler CM The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol. Psychiatry 2005; 10:105–116.
Sulser F, Vetulani J & Mobley PL Mode of action of antidepressant drugs. Biochem. Pharmacol. 1978; 27:257-261.
Sun X, Mwamburi DM, Bungay K et al. Depression, antidepressants, and plasma amyloid beta (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007; 62:1413–1417.
65
Sun X, Steffens DC, Au R et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 2008; 65:542–550.Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS; ENRICHD Investigators Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch. Gen. Psychiatry 2005; 62:792-8.
Tardito D, Perez J, Tiraboschi E, Musazi L, Racagni G, Popoli M Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview Pharmacol Rev 2006; 58:115-134.
Tham A, Engelbrektson K, Mathe AA et al. Impaired neuropsychological performance in euthymic patients with recurring mood disorders. J Clin Psychiatry 1997; 58:26–9.
Thase ME and Rush AJ When at first you don't succeed: sequential strategies for AD nonresponders. J Clin Psychiatry 1997; 58(13):23-29.
Thoenen H Neurotrophins and neuronal plasticity. Science 1995; 270:593-598.
Tong L, Thornton PL, Balazs R, Cotman CW Beta-amyloid-(1–42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem 2001; 276:17301–17306.
Tong L, Balazs R, Thornton PL, Cotman CW Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004; 24:6799–6809.
Torres IJ, Boudreau VG, Yatham LN Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand 2007; Suppl 17–26.
Toyooka K, Asama K, Watanabe Y, Muratake T, Makoto T, Someya T, Nawa H Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110:249-257. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ Effects of secreted oligomers of amyloid-beta protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572:477–492.
Trabace L, Kendrick KM, Castrignano S, Colaianna M, De Giorgi A, Schiavone S et al. Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 2007; 147:652–663.
Trejo J, Carro E, Torres-Aleman I Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 2001; 21:1628 –1634.
Trivedi MH, Rush JA Winiewski SR Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B e coll. Evaluation of outcomes with citalopram for depression using easurament-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1):28-40.
van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004; 55(4):570-575.
Van Gorp WG, Altshuler L, Theberge DC et al. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry 1998; 55:41–6.
66
Van Oijen M, Hofman A, Soares HD et al. Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective casecohort study. Lancet Neurol 2006; 5:655–660.Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348(13):1215-1222.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535–539.
Walsh DM, Selkoe DJ Abeta oligomers - a decade of discovery. J Neurochem 2007; 101:1172-1184. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL Soluble oligomers of amyloid-beta (1– 42) inhibit term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002; 924:133–140.
Wang J, Dickson DW, Trojanowski JQ, Lee VM The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 1999; 158:328–337.
Wilson RS, Barnes LL, Mendes de Leon CF et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002; 59:364–370.
Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ Two transmembrane aspartates in
presenilin-1 required for presenilin endoproteolysis and c-secretase activity. Nature 1999; 398:513–517. Wong ML & Licinio J From monoamines to genomic targets: a paradigm shift for drug discovery in
depression. Nature Rev. Drug Disc. 2004; 3:136–150.
Xu Y-L, Reinscheid RK, Hitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004; 43:487– 497.
Xu W, Kawarabayashi T, Matsubara E et al. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer’s disease and normal controls. Brain Res 2008; 1219: 169–179.
Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011 ;305(3):261-6.
Yoshimura R, Mitoma M, Sugita A et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1034– 1037.
Zachrisson OC, Balldin J, Ekman R, Naesh O, Rosengren L, Agren H, Blennow K No evident neuronal damage after ECT. Psychiatry Research 2000; 96:157-165.
Zhang YW, Thompson R, Zhang H, Xu H APP processing in Alzheimer's disease. Mol Brain 2011; 4:3. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16(1):30-39.
Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B Blood–brain barrier transport of circulating Alzheimer’s amyloid beta. Biochem Biophys Res Commun 1993; 197:1034–1040.
